This study is looking at how Netarsudil (Rhopressa), an FDA-approved eye drop for glaucoma, affects the eye's drainage system (trabecular meshwork). You could join if you are an adult with ocular hypertension or open-angle glaucoma and have good vision. Participants will either receive Netarsudil or artificial tears for about 14 days. Researchers will use special imaging to see if Netarsudil changes the spacing of the trabecular meshwork. The study aims to enroll about 50 people, but its current status is unclear.

Study design

This is a randomized, single-masked study, meaning you won't know if you're getting Netarsudil or artificial tears. About 50 participants will be enrolled.

What's involved

You would use eye drops once daily in the evening for about 14 days. You will have eye imaging at the beginning and after about 14-21 days of treatment.

Compensation

Not stated in the trial record.

Follow-up

Your eye will be imaged at baseline and again 14-21 days after starting treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.